SCHEMBL5886965

SCHEMBL5886965

Cc1nc(N2CCN(c3ccccn3)CC2)nc2c1ccc(=O)n2-c1ccc(C(=O)NCc2ccc3ccccc3c2)cc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC6A4 P31645 1/20 0.46
CTNNB1 P35222 2/20 0.44
TCF7L2 Q9NQB0 2/20 0.44
MEN1 O00255 2/20 0.42
KMT2A Q03164 2/20 0.42
POLB P06746 1/20 0.42
ALDH1A1 P00352 2/20 0.39
LMNA P02545 2/20 0.39
TSHR P16473 2/20 0.39
DRD4 P21917 1/20 0.38
KLKB1 P03952 5/20 0.37
KLK1 P06870 5/20 0.37
KDM4E B2RXH2 2/20 0.37
NPC1 O15118 1/20 0.37
TP53 P04637 1/20 0.37
GAA P10253 1/20 0.37
HPGD P15428 1/20 0.37
RAB9A P51151 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
HSD17B10 Q99714 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5887267 0.92 CTNNB1 (0.45) SLC6A4CTNNB1TCF7L2POLBALDH1A1
SCHEMBL5886709 0.90 ALDH1A1 (0.47) CTNNB1TCF7L2MEN1KMT2AALDH1A1
SCHEMBL5887120 0.90 CTNNB1 (0.44) CTNNB1TCF7L2MEN1KMT2APOLB
SCHEMBL5887063 0.89 CTNNB1 (0.45) CTNNB1TCF7L2ALDH1A1LMNAKDM4E
SCHEMBL5886856 0.88 TSHR (0.44) CTNNB1TCF7L2MEN1KMT2AALDH1A1
SCHEMBL5886921 0.88 NAMPT (0.43) CTNNB1TCF7L2MEN1KMT2AALDH1A1
SCHEMBL5886909 0.85 ALDH1A1 (0.47) CTNNB1TCF7L2MEN1KMT2APOLB
SCHEMBL5886707 0.85 ALDH1A1 (0.46) CTNNB1TCF7L2POLBALDH1A1LMNA
SCHEMBL5887163 0.85 CTNNB1 (0.46) SLC6A4CTNNB1TCF7L2MEN1KMT2A
SCHEMBL5886765 0.83 MAPT (0.48) ALDH1A1LMNANPC1TP53SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7019002-B2 Substituted on 8th position with benzoic acid, ester or amide groups; anticancer agents PHARMACIA & UPJOHN, S.P.A. (IT) 2006-03-28 US claimed
US-20040009993-A1 Pyridopyrimidinones derivatives as telomerase inhibitors PHARMACIA ITALIA S.P.A. 2004-01-15 US claimed
US-7019002-B2 Substituted on 8th position with benzoic acid, ester or amide groups; anticancer agents PHARMACIA & UPJOHN, S.P.A. (IT) 2006-03-28 US disclosed
US-20040009993-A1 Pyridopyrimidinones derivatives as telomerase inhibitors PHARMACIA ITALIA S.P.A. 2004-01-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040009993-A1 Pyridopyrimidinones derivatives as telomerase inhibitors TERT, TERF2, TERF2IP SLC6A4 4591/4885CTNNB1 1452/4885TCF7L2 381/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.